Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834261 | 1.00 | OPRM1 (0.47) | OPRM1OPRL1TRPM8FFAR1ALOX5 | |
| SCHEMBL3828306 | 1.00 | OPRM1 (0.47) | OPRM1OPRL1TRPM8FFAR1ALOX5 | |
| SCHEMBL22906968 | 0.84 | OPRM1 (0.49) | OPRM1OPRL1ALDH1A1CTSLCTSB | |
| SCHEMBL15334888 | 0.84 | OPRM1 (0.49) | OPRM1OPRL1ALDH1A1CTSLCTSB | |
| SCHEMBL13567987 | 0.84 | L3MBTL1 (0.43) | OPRM1OPRL1TRPM8FFAR1SIGMAR1 | |
| SCHEMBL13567992 | 0.84 | L3MBTL1 (0.43) | OPRM1OPRL1TRPM8FFAR1SIGMAR1 | |
| SCHEMBL19462502 | 0.79 | OPRM1 (0.47) | OPRM1OPRL1TRPM8FFAR1ALDH1A1 | |
| SCHEMBL1612308 | 0.78 | TRPM8 (0.50) | OPRM1OPRL1TRPM8ALDH1A1 | |
| SCHEMBL23908085 | 0.76 | MGLL (0.53) | OPRM1ALDH1A1 | |
| SCHEMBL12017809 | 0.76 | ALDH1A1 (0.49) | OPRM1OPRL1FFAR1ALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | OPRM1 4283/4885OPRL1 4394/4885TRPM8 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.